William Blair resumes Jasper Therapeutics stock with outperform rating
William Blair resumed coverage on Jasper Therapeutics (NASDAQ:JSPR) with an outperform rating, citing the potential of KP-104 for treating complement-mediated diseases. The firm estimates peak sales of $1.6B and expects Phase III trials in 2027. JSPR stock trades at $0.50 with a $16.49M market cap, but analysts set a $20 price target. The company reported Q2 2026 earnings beating expectations and completed an all-stock acquisition of Kira Pharmaceuticals, altering ownership structure.
How this was made
The 30-second read
Why it matters
Analyst coverage resumption adds visibility and may attract speculative interest, but the company's financial constraints and early‑stage assets keep risk high.
Market read
The news is primarily relevant to traders focused on small‑cap biotech equities.
What to watch
Potential regulatory delays and the small market cap may limit upside.
Background
Jasper Therapeutics is a micro‑cap biotech developing complement pathway inhibitors. The firm recently reported Phase II results for KP-104 and announced plans for a Phase III trial.
Ticker impact
William Blair resumed coverage on Jasper Therapeutics with an outperform rating, citing Phase II data for KP-104 and upcoming Phase III plans.
likely upward pressure as the market prices in the outperform rating and trial optimism
Coverage resumption and a high price target provide a fresh catalyst for a micro‑cap biotech that was previously under‑covered.
Market effects
May boost sentiment toward complement‑targeting biotech stocks.
Limited to U.S. biotech sector.
Minimal.
Counterpoint
The upgrade could be premature given the company's cash burn and early‑stage pipeline.
Key entities
- AnalystWilliam Blair
Equity research firm that resumed coverage with an outperform rating.
- CompanyJasper Therapeutics
Biotech developing KP-104 for complement‑mediated diseases.
